Bifogade filer
PDF
Kalender
| Tid* | ||
| 2025-02-21 | 08:30 | Bokslutskommuniké 2024 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-19 | - | Årsstämma |
| 2024-04-19 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-20 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2023-04-19 | - | Årsstämma |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-10 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2022-04-20 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-04 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2021-06-03 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-08-25 | - | Kvartalsrapport 2020-Q2 |
| 2020-02-27 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2020-02-26 | - | Årsstämma |
| 2020-02-04 | - | Bokslutskommuniké 2019 |
| 2019-05-08 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2019-05-07 | - | Årsstämma |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-08-10 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-03 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2018-05-02 | - | Årsstämma |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-08-11 | - | Kvartalsrapport 2017-Q2 |
| 2017-03-21 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2017-03-20 | - | Årsstämma |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-11-04 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-04 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-04 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2016-05-03 | - | Kvartalsrapport 2016-Q1 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-06 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cline Scientific AB (publ) ("Cline" or the "Company") has today decided to apply to put the Company into bankruptcy. The bankruptcy application is planned to be submitted today, August 12, 2024, to the Gothenburg District Court.
The reason for the bankruptcy filing is that Cline has not succeeded in resolving the financial situation that was previously communicated in the first half of 2024. The company is facing continued development costs in the two projects that have been operated, StemCART and CellRACE, which must be greatly increased in order to take these forward and thus funding for these projects needed to be secured for it to make sense to continue operations. During the last two years' financial climate, this has not been possible, the various attempts that have been made have only resulted in smaller amounts of capital, which has made the situation for continued operation unsustainable.
The company has proposed Johan Sölveland, CEO of Ackordcentralen Väst AB, Gothenburg, as bankruptcy trustee.
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.
This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 8.29 am CEST on 12 Augustl 2024.
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com